

MANNKIND CORP  
Form 8-K  
July 01, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) June 27, 2014**

**MannKind Corporation**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**000-50865**  
**(Commission**

**File Number)**

**13-3607736**  
**(IRS Employer**

**Identification No.)**

**28903 North Avenue Paine Valencia, California**  
**(Address of principal executive offices)**

**91355**  
**(Zip Code)**

**Registrant's telephone number, including area code: (661) 775-5300**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On June 27, 2014, we announced that the U.S. Food and Drug Administration (FDA) has approved AFREZZA<sup>®</sup> (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus.

A copy of the press release is attached as Exhibit 99.1 to this current report.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following exhibits are filed herewith:

- 99.1 Press Release of MannKind Corporation dated June 27, 2014, announcing FDA approval of AFREZZA<sup>®</sup> (insulin human) Inhalation Powder

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MannKind Corporation**

(Registrant)

**June 30, 2014**

(Date)

**/s/ DAVID THOMSON, PH.D., J.D.**

David Thomson, Ph.D., J.D.

*Corporate Vice President, General Counsel and  
Secretary*